Latest News From Lumira Ventures

Zymeworks Announces Updated Single Agent Data for HER2-Targeted Bispecific Antibody ZW25 at ESMO Congress 2019

Jennifer Schram Main Page, Portfolio News, Press Release, Zymeworks

BARCELONA, Spain–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced updated data from the ongoing multi-center Phase 1 clinical trial evaluating ZW25 in patients with HER2‑expressing solid tumors, including biliary tract cancer (BTC), …

Celgene Exercises Commercial Option for Zymeworks’ Azymetric™ Platform Triggering $7.5MM Milestone Payment

Jennifer Schram Main Page, Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE) — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that its global biopharma partner Celgene Corporation has selected a lead therapeutic candidate in oncology for further development and exercised its option …

Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

Jennifer Schram Portfolio News, Press Release, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform …

Zymeworks Names Anthony Polverino, Ph.D., Executive Vice President of Early Development & Chief Scientific Officer

Ahmed Khan Portfolio News, Zymeworks

September 19, 2018 06:45 AM Eastern Daylight Time VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced it has named Anthony (Tony) Polverino, Ph.D., Executive Vice President of Early Development and Chief Scientific …